secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001104659-25-121187
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech amends credit agreement with Oaktree; extends maturity to June 2028, issues warrants
--------------------------------------------------------------------------------

- Maturity extended from July 2027 to June 30, 2028; $29.5M outstanding on $35M initial borrowing.
- Principal repayment schedule set: 12.5% due Sep 30, 2027, 12.5% Dec 31, 2027, 37.5% Mar 31, 2028, 37.5% at maturity.
- Journey Medical minimum net sales covenant raised: $60M (Dec 2025) to $80M (Dec 2026 and quarterly thereafter).
- Warrants issued to lenders for 600k shares at $2.62/share, exercisable immediately, expiring July 25, 2031.
- Covenant threshold: Minimum Net Sales Test waived if outstanding principal ≤ $10M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465925121187/0001104659-25-121187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465925121187/fbio-20251212x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-121187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer